Shares in robotic surgical device company Transenterix rise by nearly 9 percent on Tuesday after the U.S. Food and Drug Administration approved its Senhance system for additional medical procedures
Read MoreTransEnterix stock rose more than 8 percent to $3.17 a share Thursday on new of its $40 million debt financing from Hercules Capital.
Read MoreRobotic surgical device company Transenterix has reached an agreement for a $40 million loan line that will allow it to expand.
Read More
TransEnterix stock got a boost from its first quarter earnings, which topped analysts estimates and suggest a healthy second quarter is likely.
Read MoreTodd Pope, the chief executive officer of TransEnterix made 23 percent more in 2017 than 2016, according to a securities filing.
Read MoreResearch Triangle Park-based TransEnertix (NYSEMKT:TRXC) stock is up nearly 9 percent to $2.31 a share in pre-market trading Tuesday following news that it has agreed to sell its SurgiBot system to a Chinese firm for $29 million. The FDA rejected TransEnterix’s Surgibot submission last year. The medical device company agreed to transfer ownership of the SurgiBot line to China’s Great Belief International Limited (GBIL). TranEnterix will receive $7.5 million by the end of December and another $7.5 million by March, 2018. The second payment includes a $3 million equity investment in Transeneterix common stock at $2.33 a share. The...
Read More
